

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070746 A2(51) International Patent Classification?: **C07K**

Antonio Gonçalves da Cruz St., RM 111A, 05503-900 São Paulo (BR).

(21) International Application Number: **PCT/BR03/00012**

(22) International Filing Date: 29 January 2003 (29.01.2003)

(72) Inventor; and

(25) Filing Language: **English**(75) Inventor/Applicant (for US only): **REIS, Cleyson** [BR/BR]; Instituto Butantan, Centro de Toxicologia Aplicada - CAT/CEPID, 1500 Vital Brasil Av., 05503-900 São Paulo (BR).(26) Publication Language: **English**(30) Priority Data:
PI0200269-8 31 January 2002 (31.01.2002) **BR**(74) Agent: **LLC INFO CONNECTION LTDA.**; 60 Hermenegarda St., RM 403. Méier, 20710-010 Rio de Janeiro (BR).(71) Applicants (for all designated States except US): **BIOLAB SANUS FARMACÊUTICA LTDA.** [BR/BR]; 5386 dos Bandeirantes Av., Planalto Paulista, 04071-900 São Paulo (BR). **FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP** [BR/BR]; 1500 Pío XI St., Alto da Lapa, 05468-901 São Paulo (BR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant and

(72) Inventor: **CHUDZINSKI-TAVASSI, Ana** [BR/BR]; 60

[Continued on next page]

(54) Title: PURIFYING PROCESS OF SOLUBLE PROTEINS OF THE *L. OBLIQUA* BRISTLES THROUGH PROTHROMBIN ACTIVATION; PROCESS FOR A PARTIAL DETERMINATION OF THE AMINO ACIDS SEQUENCE OF THE PROTHROMBIN ACTIVATOR; PROCESS FOR DETERMINING THE PROTHROMBIN ACTIVATION OF FRACTION II, N-TERMINAL AND INTERNAL FRAGMENTS SEQUENCES

(57) Abstract: The herein invention refers to a purifying process of soluble proteins of the *L. obliqua* bristles through prothrombin activation; a partial determination of the amino acids sequence of the prothrombin activator; a process for determining the fraction II of the prothrombin activation as well as the N-terminal sequence and the sequence of internal fragments of the prothrombin activator fraction, the prothrombin activator and the utilization of the prothrombin activator through the homogenization of the *L. obliqua* bristles. The herein invention has shown that only one component of the *Lonomia obliqua* venom, the Lopap, causes the hemorrhagic syndrome directly by activating prothrombin and, therefore, a patient should be conducted to a therapy when in contact with the *Lonomia obliqua* venom. According to the herein invention, Lopap is a new prothrombin activator, showing to be a quite important factor responsible for consumption coagulopathy, found in patients exposed to the venom of the *L. obliqua* caterpillar. In low doses of purified protein, due to its capacity of activating prothrombin and generating thrombin, it is possible, in controlled conditions, to withdraw fibrinogen from circulation, transforming it in fibrin microthrombs. The decrease on the concentration of plasmatic fibrinogen promotes the increasing of blood coagulation time and therefore it will avoid acute vascular thrombosis. Since protein does not present proteolytic activity, it could maintain the coagulating capacity of the fibrinogen not consumed in the process. The fibrinogen plasmatic concentration would decrease, however there would not be predisposition for hemorrhagic state. Besides that, it could be used to produce diagnosis KITS for detecting dysprothrombinemias.